Fresenius invests in BioIntelliSense

费森尤斯投资美国医疗数据服务公司BioIntelliSense,具体金额未披露

2019-07-11 10:36:00 mass

本文共271个字,阅读需1分钟

Fresenius Medical Care  today announced an investment in BioIntelliSense for an undisclosed amount. Denver-based BioIntelliSense is developing a medical-grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. Through the agreement, Fresenius will use the advanced analytics and artificial intelligence to develop medical wearables for clinical pathways that allow clinicians to be alerted for early intervention of medical conditions. The company says the combination of the two technologies can help prevent complications and reduce unnecessary and costly hospitalizations. Fresenius earlier this month expanded into clinical research activities into kidney research.
费森尤斯(Fresenius) Medical Care 今日宣布投资 BioIntelliSense ,金额不详。 总部位于丹佛的 BioIntelligse 公司正在开发一个医疗级别的数据服务平台,用于持续远程健康监测、预测分析和算法临床洞察。 通过该协议,费森尤斯(Fresenius)将利用先进的分析和人工智能,为临床路径开发医用可穿戴设备,使临床医生在早期干预医疗状况时得到提醒。该公司表示,这两种技术的结合可以帮助预防并发症,减少不必要和昂贵的住院费用。 本月早些时候,费森尤斯(Fresenius)扩大到肾脏研究的临床研究活动。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文